What were the key results of the Wisman PMA Study?

• A. There was no measurable difference.
• B. Hemostasis under 5 minutes improved only in the 5-minute window.
• C. 90.3% vs. 80.4% hemostasis in under 5 minutes; 50.3% vs. 32.9% in under 1 minute.
• D. Hemostasis worsened with Arista.

Answer: (C)

The main idea being tested is how quickly and reliably a hemostatic agent stops surgical bleeding. In the Wisman PMA Study, the product achieved higher hemostasis rates in both the 5-minute and 1-minute timeframes. Specifically, 90.3% of cases reached hemostasis within 5 minutes with the product versus 80.4% with the comparator, and 50.3% reached it within 1 minute versus 32.9% with the comparator. This shows faster onset and a greater likelihood of rapid bleeding control, illustrating the agent’s improved effectiveness in surgical use. The other options imply no difference, a smaller improvement, or worsening, which these results do not support.